With over 2000 deaths each year in the United States, sudden infant death syndrome (SIDS) remains a leading cause of death in infants under 1 year of age. In order to reach the ultimate goal of the NICHD to eradicate this emotionally devastating syndrome, it is vital to understand the underlying etiologies and pathogenesis of this multifactorial syndrome. However, the fundamental causes of SIDS remain poorly understood. Underlying genetic susceptibility for sudden death, involving genetic determinants of the central nervous system and serotonergic signaling, immune dysfunction, metabolism/energy pathway, nicotine response, and cardiac repolarization, may represent pathogenic substrates for infant vulnerability in accordance with the SIDS triple risk hypothesis for a significant number of SIDS cases. The genetics of SIDS is most likely multigenic and complex yet there has been no studies performed to elucidate the global genetic load. Through the use of monumental technological advances in genomic research, including array comparative genomic hybridization (aCGH) and next-generation whole- exome DNA sequencing (WES), it is our broad objective to perform the first whole genome interrogation of one of the world's largest assembled, multi-ethnic SIDS cohorts (n=625; 303 Caucasian, 203 African American, 96 Hispanic, 14 Asian, and 9 mixed race) in order 1) to explore the novel concept of increased radical de novo mutation (DNM) rate among SIDS victims as a paradigm shift in explaining the paradoxical sustained world-wide prevalence of SIDS by performing aCGH and WES on SIDS case-parent trios, 2) to establish the spectrum, prevalence, and biological pathway involvement of copy number variations (CNV) as an underlying genetic susceptibility for SIDS, and 3) to establish a Genetic Blueprint of Infant Vulnerability across multiple disciplines using WES and pathway/network analysis of genes identified with rare non-synonymous genetic variants, to ascertain whether specific SIDS-associated molecular biological pathways (i.e. serotonergic pathways, immune response deficiencies, cardiac repolarization abnormalities, etc.) or signaling networks are predominantly effected. The proposed experiments will test our three-fold hypothesis that 1) rare DNMs with clear functional significance will be identified in novel SIDS-susceptibility genes and pathways and the underlying DNM rate, defined as the ratio of non-synonymous (NS) to synonymous DNMs, and the ratio of nonsense to missense DNMs in SIDS will exceed the ratio previously established in healthy living subjects, 2) a significant number of SIDS cases are due to rare CNVs typified as deletions and/or duplications of DNA segments of e 1kilobase in length that alter either imbalances of dosage or disruption of neurodevelopmental, CNS signaling, metabolic, immunologic, and/or cardiac channelopathic genes, and 3) rare genetic variants in SIDS will be over-dispersed to genes comprising SIDS-susceptibility pathways with classical (2 to 4 months of age) SIDS cases harboring an increase burden of rare variants in a neurodevelopmental pathways while non-classical (<2 months or > 4 months) SIDS cases will harbor an increased burden of rare variants in metabolic, immunologic, or channelopathic pathway(s).

Public Health Relevance

Over 2000 seemingly healthy infants die inexplicably each year, a sudden, unexpected, and unexplained death labeled as sudden infant death syndrome (SIDS). The purpose of this study is to discover fundamental pathogenic causes/substrates for the 'infant vulnerability' that underlies SIDS with a focus on genes that regulate the heart's electrical system, central and autonomic nervous system, immune system, metabolism, and nicotinergic/serotonergic response systems.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD042569-14
Application #
9293903
Study Section
Pregnancy and Neonatology Study Section (PN)
Program Officer
Higgins, Rosemary
Project Start
2002-06-07
Project End
2018-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
14
Fiscal Year
2017
Total Cost
$541,808
Indirect Cost
$189,614
Name
Mayo Clinic, Rochester
Department
Type
Other Domestic Non-Profits
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Giudicessi, John R; Wilde, Arthur A M; Ackerman, Michael J (2018) The genetic architecture of long QT syndrome: A critical reappraisal. Trends Cardiovasc Med 28:453-464
Clemens, Daniel J; Lentino, Anne R; Kapplinger, Jamie D et al. (2018) Using the genome aggregation database, computational pathogenicity prediction tools, and patch clamp heterologous expression studies to demote previously published long QT syndrome type 1 mutations from pathogenic to benign. Heart Rhythm 15:555-561
Giudicessi, John R; Ackerman, Michael J (2018) Role of genetic heart disease in sentinel sudden cardiac arrest survivors across the age spectrum. Int J Cardiol 270:214-220
Männikkö, Roope; Wong, Leonie; Tester, David J et al. (2018) Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. Lancet 391:1483-1492
Lane, Conor M; Giudicessi, John R; Ye, Dan et al. (2018) Long QT syndrome type 5-Lite: Defining the clinical phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common genetic variant. Heart Rhythm 15:1223-1230
Giudicessi, J R; Ackerman, M J; Camilleri, M (2018) Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil 30:e13302
Kapplinger, Jamie D; Pundi, Krishna N; Larson, Nicholas B et al. (2018) Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. Circ Genom Precis Med 11:e001424
Paquin, Ashley; Ye, Dan; Tester, David J et al. (2018) Even pore-localizing missense variants at highly conserved sites in KCNQ1-encoded Kv7.1 channels may have wild-type function and not cause type 1 long QT syndrome: Do not rely solely on the genetic test company's interpretation. HeartRhythm Case Rep 4:37-44
Giudicessi, John R; Kullo, Iftikhar J; Ackerman, Michael J (2017) Precision Cardiovascular Medicine: State of Genetic Testing. Mayo Clin Proc 92:642-662
Giudicessi, John R; Ackerman, Michael J (2016) Calcium Revisited: New Insights Into the Molecular Basis of Long-QT Syndrome. Circ Arrhythm Electrophysiol 9:

Showing the most recent 10 out of 126 publications